Monte Rosa Therapeutics, Inc. (GLUE) earnings
GLUE earnings moved a median of -0.91% by the close. Quarterly and annual GLUE reports and results, each read against the price at its own news timestamp. Back to the GLUE overview →
22 measured GLUE earnings events.
Where these GLUE earnings landedvs 22 measured GLUE earnings reactions
| Middle 50% of GLUE earnings reactions | -3.08% to +2.92% |
|---|---|
| Median reaction (to close) | -0.91% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 GLUE earnings events with a measured close landed between -3.08% and +2.92%; 45% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Monte Rosa Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.02% | +0.58% | |
| Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Press release | +1.02% | +0.58% | |
| Form 10-Q Monte Rosa Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.15% | -2.17% | |
| Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Press release | -0.15% | -2.17% | |
| Form 10-K Monte Rosa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.92% | -0.68% | |
| Form 10-Q Monte Rosa Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.04% | +4.92% | |
| Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates | Press release | -0.04% | +4.92% | |
| Form 10-Q Monte Rosa Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.95% | -3.20% | |
| Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates | Press release | -1.95% | -3.20% | |
| Form 10-Q Monte Rosa Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -5.59% | -5.59% | |
| Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates | Press release | -5.59% | -5.59% | |
| Form 10-K Monte Rosa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.07% | +9.29% | |
| Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs | Press release | -1.07% | +9.29% | |
| Form 10-Q Monte Rosa Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.74% | +0.74% | |
| Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.74% | +0.74% | |
| Form 10-Q Monte Rosa Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.82% | +3.65% | |
| Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.82% | +3.65% | |
| Form 10-Q Monte Rosa Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.10% | -1.15% | |
| Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.10% | -1.15% | |
| Form 10-K Monte Rosa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -7.02% | |
| Form 10-Q Monte Rosa Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -2.73% | |
| Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | +1.91% | -10.08% |
Keep exploring
More GLUE: analyst actions → · SEC filings → · GLUE overview →